Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Recipient : Compass Pathways
Deal Size : Undisclosed
Deal Type : Collaboration
Compass Pathways Partners with Hackensack Meridian to Optimize COMP360 Psilocybin Model
Details : The collaboration aims to inform the delivery model design of investigational COMP360, a proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD).
Brand Name : COMP360
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : Compass Pathways
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?